Mandate

Vinge has advised Tobii in connection with the listing of Tobii Dynavox

Vinge has advised Tobii and Tobii Dynavox in connection with the distribution of the shares in Tobii Dynavox to the shareholders in Tobii as well as the listing of Tobii Dynavox’s ordinary shares on Nasdaq Stockholm. The prospectus was published 23 November 2021 and the first day of trading on Nasdaq Stockholm was 9 December 2021.

Tobii Dynavox is the global leader in assistive technology for communication. The company’s custom designed solutions enable people with disabilities such as cerebral palsy, ALS and spinal cord injury to communicate with a voice of their own, develop literacy skills and live more independently. To date, hundreds of thousands of people worldwide have benefited from their integrated solutions, which include hardware, software, clinically developed language systems, special education tools, training, and dedicated support. The company offers an extensive funding support system to reach as many people as possible. Headquartered in Sweden, Tobii Dynavox employs around 500 people with offices in the US, the UK, Norway and China, and reselling partners in 60+ countries.

Vinge’s team consisted of Jesper Schönbeck, Amanda Knutsson, Joel Magnusson, Emil Lindwall, Pernilla Björklund, Henrik Wastensson, Victor Ericsson and Emelie Svanberg,Maria Dahlin Kolvik, Christina Odengran, Ellinor Wargenbrant, Eléonore Friberg, Jolene Reimerson and Viktoria Owetz Leyva.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025